Figure 4.
BR101801 shows superior anti-cancer effects than verified PI3K inhibitors idelalisib or TGR-1202. A. BR101801 treatment increased cell population in G0/G1 more than idelalisib or TGR-1202. B. SU-DHL-6 cells were treated with idelalisib, TGR-1202, and BR101801 (1 nM) for 24 h followed by Western blot analysis with the indicated antibodies. C. BR101801 induced more apoptosis in DOHH-2 cells than idelalisib or TGR-1202.
